FRIDAY, Feb. 7, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of...

Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug for weight...

The promise of help with weight loss is always alluring. But what if that solution comes with a few hidden risks?In South Africa, where obesity rates...

THURSDAY, Jan. 30, 2025 -- The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA)...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent pharmaceutical advances...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor agonists.

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor agonists.

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity. The dramatic effects of these drugs,...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with...